<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29217683</article-id>
<article-id pub-id-type="pmc">5783959</article-id>
<article-id pub-id-type="publisher-id">2010-17</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.2010-17.2017</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
<subj-group>
<subject>Neurobiology of Disease</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-6151-1096</contrib-id>
<name>
<surname>Steinmetz</surname>
<given-names>Adam B.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stern</surname>
<given-names>Sarah A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kohtz</surname>
<given-names>Amy S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Descalzi</surname>
<given-names>Giannina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-7386-0018</contrib-id>
<name>
<surname>Alberini</surname>
<given-names>Cristina M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Center for Neural Science, New York University, New York, New York, 10003</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to Dr. Cristina M. Alberini,
<addr-line>Center for Neural Science, New York University, 4 Washington Place, New York, NY, 10003.</addr-line><email>ca60@nyu.edu</email></corresp>
<fn fn-type="con">
<p>Author contributions: A.B.S., S.A.S., A.S.K., and C.M.A. designed research; A.B.S., S.A.S., A.S.K., and G.D. performed research; A.B.S., S.A.S., A.S.K., G.D., and C.M.A. analyzed data; A.B.S., S.A.S., A.S.K., and C.M.A. wrote the paper.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>24</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>24</day>
<month>7</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>38</volume>
<issue>4</issue>
<fpage>1015</fpage>
<lpage>1029</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>7</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>18</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 the authors 0270-6474/18/371015-15$15.00/0</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="zns00418001015.pdf"></self-uri>
<abstract>
<p>Autism spectrum disorder (ASD) is a developmental disability characterized by impairments in social interaction and repetitive behavior, and is also associated with cognitive deficits. There is no current treatment that can ameliorate most of the ASD symptomatology; thus, identifying novel therapies is urgently needed. We used male BTBR <italic>T</italic><sup>+</sup>
<italic>Itpr3<sup>tf</sup></italic>/J (BTBR) mice, a model that reproduces most of the core behavioral phenotypes of ASD, to test the effects of systemic administration of insulin-like growth factor II (IGF-II), a polypeptide that crosses the blood–brain barrier and acts as a cognitive enhancer. We show that systemic IGF-II treatments reverse the typical defects in social interaction, cognitive/executive functions, and repetitive behaviors reflective of ASD-like phenotypes. In BTBR mice, IGF-II, via IGF-II receptor, but not via IGF-I receptor, reverses the abnormal levels of the AMPK-mTOR-S6K pathway and of active translation at synapses. Thus, IGF-II may represent a novel potential therapy for ASD.</p>
<p><bold>SIGNIFICANCE STATEMENT</bold> Currently, there is no effective treatment for autism spectrum disorder (ASD), a developmental disability affecting a high number of children. Using a mouse model that expresses most of the key core as well as associated behavioral deficits of ASD, that are, social, cognitive, and repetitive behaviors, we report that a systemic administration of the polypeptide insulin-like growth factor II (IGF-II) reverses all these deficits. The effects of IGF-II occur via IGF-II receptors, and not IGF-I receptors, and target both basal and learning-dependent molecular abnormalities found in several ASD mice models, including those of identified genetic mutations. We suggest that IGF-II represents a potential novel therapeutic target for ASD.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorder</kwd>
<kwd>insulin-like growth factor II receptor</kwd>
<kwd>insulin-like growth factor II</kwd>
<kwd>memory</kwd>
<kwd>mouse model</kwd>
<kwd>mTOR</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>